Medicinal Chemistry, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Medicinal Chemistry, Research and Early Development, Respiratory & Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
J Pharm Biomed Anal. 2022 Mar 20;211:114518. doi: 10.1016/j.jpba.2021.114518. Epub 2021 Dec 11.
The inhalation of peptides comes with the advantage of directly targeting the lung as tissue of interest. However, peptides are often rapidly metabolized in lung tissue through proteolytic cleavage. We have developed an assay workflow to obtain half-life and metabolite ID data for peptides incubated with four proteases abundant in lungs of asthma and COPD patients. The assay system has been validated using 28 structurally diverse linear and cyclic peptides with a molecular weight between 708 and 5808 Da. Experimental conditions for incubation, sample preparation, chromatography, data acquisition and analysis are compatible with the required throughput in early stage peptide projects. Together with co-crystal structures and Ala scans, we are using the described assay workflow to guide the first chemical modifications of peptide hits in early respiratory drug discovery projects.
吸入肽具有直接靶向肺部作为目标组织的优势。然而,肽在肺部组织中常常通过蛋白水解切割而迅速代谢。我们开发了一种分析工作流程,用于获得与在哮喘和 COPD 患者肺部中丰富的四种蛋白酶孵育的肽的半衰期和代谢物 ID 数据。该分析系统已经使用分子量在 708 至 5808 Da 之间的 28 种结构不同的线性和环状肽进行了验证。孵育、样品制备、色谱、数据采集和分析的实验条件与早期肽项目所需的通量兼容。结合共晶结构和 Ala 扫描,我们正在使用描述的分析工作流程来指导早期呼吸药物发现项目中肽命中的第一次化学修饰。